FDA-cleared profile

LVivo Software Application

DiA Imaging Analysis Ltd. · Ultrasound · FDA-cleared (510(k))

Non-invasive processing of ultrasound images to detect, measure, and calculate relevant medical parameters of structures and function in patients with suspected disease, with Quality Score feedback.

Clinical role
Offline post-acquisition DICOM-clip analysis with automated frame selection, measurements, quality feedback, manual adjustment or editing, and visual confirmation as part of standard echocardiographic assessment.
Images and patients
Ultrasound · Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
Key limitation
The FDA indication is broad, while the reported validation cohort included adults aged 18 years or older in sinus rhythm without multiple premature beats and excluded patients with LBBB. The packet reports 99 of 121 exams automatically analyzed and 90% of 40 additional PLAX exams automatically analyzed; results require clinical review and the study criteria do not establish performance for all patient or rhythm groups.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyUltrasound · Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
  • Workflow roleOffline post-acquisition DICOM-clip analysis with automated frame selection, measurements, quality feedback, manual adjustment or editing, and visual confirmation as part of standard echocardiographic assessment.
  • Required inputDICOM echocardiographic movies or clips from any vendor, including apical 2CH, 3CH, and 4CH views and parasternal short-axis and long-axis views; the platform also processes clips for RV and bladder evaluation.
  • Output and human actionQuality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Non-invasive processing of ultrasound images to detect, measure, and calculate relevant medical parameters of structures and function in patients with suspected disease, with Quality Score feedback.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Offline post-acquisition DICOM-clip analysis with automated frame selection, measurements, quality feedback, manual adjustment or editing, and visual confirmation as part of standard echocardiographic assessment.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM echocardiographic movies or clips from any vendor, including apical 2CH, 3CH, and 4CH views and parasternal short-axis and long-axis views; the platform also processes clips for RV and bladder evaluation.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Quality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Routine transthoracic echocardiography and point-of-care echo workflow; the FDA packet does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The FDA indication is broad, while the reported validation cohort included adults aged 18 years or older in sinus rhythm without multiple premature beats and excluded patients with LBBB. The packet reports 99 of 121 exams automatically analyzed and 90% of 40 additional PLAX exams automatically analyzed; results require clinical review and the study criteria do not establish performance for all patient or rhythm groups.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
FDA clinical validation used 121 routine transthoracic echocardiography patients; 99 exams (82%) were automatically analyzed. The primary endpoint was correlation of Fractional Shortening against the average manual measurements of two sonographers, r=0.79, with an acceptance criterion of at least 0.75. Sensitivity and specificity were each 85% at a 28% cutoff. An additional 40-patient U.S. dataset had 90% automatic analysis; the retrieved exact text states that PLAX results are provided below but does not expose the numeric table values.
  • Exact FDA submission
  • Checked 2026-09-19

The retrieved exact text supports the 121-patient and 40-patient study facts but does not expose the numeric PLAX correlation range in the active dossier.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA clinical validation used 121 routine transthoracic echocardiography patients; 99 exams (82%) were automatically analyzed. The primary endpoint was correlation of Fractional Shortening against the average manual measurements of two sonographers, r=0.79, with an acceptance criterion of at least 0.75. Sensitivity and specificity were each 85% at a 28% cutoff. An additional 40-patient U.S. dataset had 90% automatic analysis; the retrieved exact text states that PLAX results are provided below but does not expose the numeric table values.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The retrieved exact text supports the 121-patient and 40-patient study facts but does not expose the numeric PLAX correlation range in the active dossier.

Reported sensitivity
85% at the prespecified 28% cutoff.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

The prior 28% values were the cutoff, not sensitivity or specificity; FDA K240553 reports 85% for each endpoint at that cutoff.

Reported specificity
85% at the prespecified 28% cutoff.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08

The prior 28% values were the cutoff, not sensitivity or specificity; FDA K240553 reports 85% for each endpoint at that cutoff.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

LVivo Software Application regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240553
  • Samplen=121
  • IndependenceIndependence not established

K240553

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240553. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM echocardiographic movies or clips from any vendor, including apical 2CH, 3CH, and 4CH views and parasternal short-axis and long-axis views; the platform also processes clips for RV and bladder evaluation.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K240553: LVivo Software Application

  2. Routing

    Source context, not route validation: Processes off-line DICOM clips from any vendor on Windows or Linux, with an Android option for LVivo EF noted in the comparison table. The FDA packet does not establish a specific PACS, RIS, EHR, cloud, or local interface contract.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240553: LVivo Software Application

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Quality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K240553: LVivo Software Application

  5. Viewer/worklist/report

    Unresolved route: Quality Score feedback plus EF, strain, segmental wall motion, RV, SAX, PLAX, and bladder results; automated LV size and function parameters and measurements with user visualization and editing or confirmation.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K240553: LVivo Software Application

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Processes off-line DICOM clips from any vendor on Windows or Linux, with an Android option for LVivo EF noted in the comparison table. The FDA packet does not establish a specific PACS, RIS, EHR, cloud, or local interface contract.
  • Exact FDA submission
  • Checked 2026-09-08

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for LVivo Software Application; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240553
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Heart and cardiovascular structures, especially the left and right ventricles; a bladder-volume module is also described
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-10-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
23Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not name the intended users of the subject device. Confirm intended operators and readers with the vendor.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240553 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 2 history items

Source ledger

  1. FDA K240553: LVivo Software Application

    U.S. Food and Drug Administration - Published 2024-10-04 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. LVivo Software Application model card (K240553)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240553

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K240553 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K251368

FETOLY

Diagnoly

Authorized purpose: FETOLY analyzes fetal ultrasound images and sequences to detect labeled fetal brain and heart views, assess image completeness or quality, and provide fetal biometric measurements during the second and third trimesters.

Modality
Ultrasound
Anatomy
Fetal heart and fetal brain
Decision
2025-09-12
FDA-cleared K222970

LVivo IQS

DiA Imaging Analysis Ltd

Non-invasive processing of ultrasound images to detect, measure, and calculate medical parameters of structures and function in patients with suspected disease, with Quality Score feedback; the submitted IQS module provides real-time quality scoring for the left ventricle from the four-chamber apical view.

Modality
Ultrasound
Anatomy
Heart; left ventricle from the four-chamber apical view
Decision
2023-02-01

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history